Skip to main content
    P

    PDS Biotechnology Corp (PDSB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.92
    +0.05 (+5.90%)

    Market Cap: $107.07M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    PDS Biotechnology Corp (PDSB) Earnings: Report Dates and Results

    Updated Nov 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    PDS Biotechnology (PDSB) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, PDS Biotechnology reported EPS of -$0.11, below the -$0.09 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    58%(22/38)
    Avg Surprise
    -23.64%

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.09
    Range-$0.09 - -$0.09
    4 analysts
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts

    Next Report

    PDSB has an expected report date of Mar 29, 2027.

    PDSB Earnings Call

    The latest PDSB earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, PDSB beat 22 and missed 16. The widest gap in the table came in the quarter ended Sep 30, 2018, when EPS landed 748.15% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.11-$0.09-$0.11 - -$0.07-22.22%MissN/A21 up, 0 downNov 13, 2026
    Jun 30, 2026-$0.18-$0.13-$0.14 - -$0.12-38.46%MissN/A30 up, 0 downAug 13, 2026
    Mar 31, 2026-$0.13-$0.14-$0.15 - -$0.13+7.14%BeatN/A20 up, 0 downMay 13, 2026
    Dec 31, 2025-$0.14-$0.18N/A+20.77%BeatN/A11 up, 0 downMar 30, 2026
    Sep 30, 2025-$0.19-$0.20N/A+5.00%BeatN/A23 up, 0 downNov 13, 2025
    Jun 30, 2025-$0.21-$0.23-$0.25 - -$0.22+8.70%BeatN/A32 up, 1 downAug 13, 2025
    Mar 31, 2025-$0.21-$0.25-$0.31 - -$0.19+16.00%BeatN/A32 up, 0 downMay 14, 2025
    Dec 31, 2024-$0.21-$0.28-$0.29 - -$0.25+23.64%BeatN/A42 up, 1 downMar 27, 2025
    Sep 30, 2024-$0.29-$0.28-$0.33 - -$0.26-3.57%MissN/A52 up, 0 downNov 14, 2024
    Jun 30, 2024-$0.23-$0.33-$0.40 - -$0.29+30.30%BeatN/A51 up, 0 downAug 13, 2024
    Mar 31, 2024-$0.30-$0.37-$0.45 - -$0.28+18.92%BeatN/A60 up, 0 downMay 15, 2024
    Dec 31, 2023-$0.35-$0.42-$0.60 - -$0.37+16.67%BeatN/A70 up, 0 downMar 27, 2024
    Sep 30, 2023-$0.35-$0.47-$0.50 - -$0.32+25.53%BeatN/A70 up, 0 downNov 14, 2023
    Jun 30, 2023-$0.37-$0.34-$0.39 - -$0.29-8.82%MissN/A70 up, 0 downAug 14, 2023
    Mar 31, 2023-$0.32-$0.30-$0.36 - -$0.25-6.67%MissN/A70 up, 0 downMay 15, 2023
    Dec 31, 2022-$0.67-$0.29-$0.33 - -$0.26-131.03%MissN/A70 up, 0 downMar 28, 2023
    Sep 30, 2022-$0.26-$0.28-$0.32 - -$0.23+7.14%BeatN/A70 up, 0 downNov 14, 2022
    Jun 30, 2022-$0.20-$0.28-$0.34 - -$0.15+28.57%BeatN/A60 up, 0 downAug 8, 2022
    Mar 31, 2022-$0.32-$0.22-$0.26 - -$0.18-45.45%MissN/A50 up, 0 downMay 11, 2022
    Dec 31, 2021-$0.22-$0.24-$0.28 - -$0.18+8.33%BeatN/A6N/AMar 31, 2022
    Sep 30, 2021-$0.23-$0.20-$0.27 - -$0.17-15.00%MissN/A6N/ANov 10, 2021
    Jun 30, 2021-$0.22-$0.16-$0.24 - -$0.12-37.50%MissN/A7N/AAug 12, 2021
    Mar 31, 2021-$0.14-$0.17-$0.23 - -$0.17+17.65%BeatN/A4N/AMay 13, 2021
    Dec 31, 2020-$0.18-$0.19-$0.20 - -$0.18+5.26%BeatN/A3N/AMar 18, 2021
    Sep 30, 2020-$0.23-$0.14-$0.27 - -$0.14-64.29%MissN/A2N/ANov 11, 2020
    Jun 30, 2020-$0.19-$0.23-$0.26 - -$0.20+17.39%BeatN/A2N/AAug 13, 2020
    Mar 31, 2020-$0.39-$0.15-$0.15 - -$0.15-160.00%Miss-126.5%1N/AMay 13, 2020
    Dec 31, 2019-$0.84-$0.92-$1.00 - -$0.85+8.70%BeatN/A2N/AMar 27, 2020
    Sep 30, 2019-$0.92-$0.82N/A-12.20%MissN/AN/AN/ANov 7, 2019
    Jun 30, 2019-$0.75N/AN/AN/AN/AN/AN/AN/AAug 1, 2019
    Mar 31, 2019$1.47N/AN/AN/AN/AN/AN/AN/AMay 14, 2019
    Dec 31, 2018-$0.10-$2.60N/A+96.15%BeatN/AN/AN/AFeb 21, 2019
    Sep 30, 2018-$2.29-$0.27N/A-748.15%MissN/AN/AN/ANov 1, 2018
    Jun 30, 2018-$8.20-$10.52N/A+22.05%BeatN/AN/AN/AAug 1, 2018
    Mar 31, 2018-$13.40-$10.52N/A-27.38%MissN/AN/AN/AMay 1, 2018
    Dec 31, 2017-$9.00-$8.62N/A-4.41%MissN/AN/AN/AMar 1, 2018
    Sep 30, 2017-$7.40-$9.55N/A+22.51%BeatN/AN/AN/ANov 1, 2017
    Jun 30, 2017-$8.80-$8.74N/A-0.69%MissN/AN/AN/AAug 1, 2017
    Mar 31, 2017-$8.40-$8.45N/A+0.59%BeatN/AN/AN/AMay 3, 2017
    Dec 31, 2016-$6.60-$8.31N/A+20.58%BeatN/AN/AN/AMar 2, 2017
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.75, after -$1.03 the year before. It was -$27.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.75N/A
    Dec 31, 2024-$1.03N/A
    Dec 31, 2023-$1.39N/A
    Dec 31, 2022-$1.45N/A
    Dec 31, 2021-$0.81N/A
    Dec 31, 2020-$0.99N/A
    Dec 31, 2019-$1.04N/A
    Dec 31, 2018-$23.99N/A
    Dec 31, 2017-$33.60N/A
    Dec 31, 2016-$27.00N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 2,000 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20261,9767
    2025Q4Dec 31, 20252,7097
    2025Q3Sep 30, 20253,8797
    2025Q2Jun 30, 20253,0326
    2025Q1Mar 31, 20253,9888
    2024Q3Sep 30, 20244,2108

    2026Q1 Earnings Call

    Opening remarks

    Dean Schwartz Host / Investor Relations Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's First Quarter 2026 Results and Clinical Programs update call. I'm joined on the call today by the following members of the company's management team: Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Kirk Shepard, Chief Medical Officer; and Lars Boesgaard, Chief Financial Officer. Dr. Bedu-Addo and Dr. Shepard will provide an overview of the company's recent highlights in its clinical development program, and Mr. Boesgaard will review the financial results for the quarter ended March 31, 2026. Following management's prepared remarks, we will take questions from covering analysts. As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our quarterly reports on Form 10-Q and annual report on Form 10-K and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information. Now I'd like to turn the call over to Dr. Bedu-Addo. Frank?

    Frank Bedu-Addo Chief Executive Officer Thank you, Dean, and good morning, everyone. It's our pleasure to speak with you again and to provide this brief update on our progress in advancing our clinical programs. This past quarter, our major focus was on advancing our clinical programs and we made significant progress. So I will hand the call over to our Chief Medical Officer, Dr. Kirk Shepard, to provide an update. Kirk?

    Kirk Shepard Chief Medical Officer Thank you, Frank. During our first quarter, we adopted an amendment to our VERSATILE-003 trial, revising the design to incorporate progression-free survival as an interim primary endpoint which we believe has the potential to enable a more efficient path to accelerated approval. We also believe this amendment may shorten the trial's duration and reduce the overall costs, all while retaining overall survival as a basis for full approval in accordance with FDA requirements. Additionally, this approach may also accelerate the availability of this promising treatment to the rapidly growing population of HPV16-positive patients in dire need of effective treatment. For patients living with HPV16-positive head and neck cancer, a disease with significant and growing unmet need, we believe PDS0101 represents a promising treatment option, and we remain focused on advancing it as efficiently as possible. PDS0101 in combination with KEYTRUDA (pembrolizumab) is the only late-stage investigational head and neck squamous cell carcinoma therapy that requires only 5 doses and is also the only subcutaneous therapy.

    Frequently Asked Questions About PDSB

    When is PDS Biotechnology's next earnings date?

    PDS Biotechnology's next earnings report is expected for Mar 29, 2027.

    Did PDSB beat earnings estimates last quarter?

    No. PDS Biotechnology reported EPS of -$0.11 for the quarter ended Sep 30, 2026, below the -$0.09 estimate by 22.22%.

    What EPS do analysts expect from PDSB next quarter?

    The consensus EPS estimate for PDS Biotechnology for the quarter ending Dec 31, 2026 is -$0.09 from 4 analysts, with estimates from -$0.09 to -$0.09.

    How often does PDSB beat earnings estimates?

    PDS Biotechnology beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +2.57%.